Clinical Trials Logo

Allergic Rhinitis clinical trials

View clinical trials related to Allergic Rhinitis.

Filter by:

NCT ID: NCT00794794 Completed - Allergic Rhinitis Clinical Trials

Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03826)

Start date: November 2004
Phase: Phase 3
Study type: Interventional

This study was conducted to compare the taste acceptability of Zyrtec syrup with desloratadine syrup in children. Children between 6 and 11 years of age received 5 mL of each syrup, separated by 15 to 20 minutes on a single day.

NCT ID: NCT00794378 Completed - Allergic Rhinitis Clinical Trials

Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03829)(COMPLETED)

Start date: November 2004
Phase: Phase 3
Study type: Interventional

This study was conducted to compare the taste acceptability of Zyrtec syrup with desloratadine syrup in children. Children between 6 and 11 years of age received 5 mL of each syrup, separated by 15 to 20 minutes on a single day.

NCT ID: NCT00794144 Completed - Allergic Rhinitis Clinical Trials

Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age

Start date: October 2008
Phase: Phase 2
Study type: Interventional

The purpose of the study is to assess the safety of the study drug, Patanase (Olopatadine Hydrochloride Nasal Spray 0.6%) compared to placebo (inactive substance) in children ages 2 to less than 6 who have a history of nasal allergies, and to assess the pharmcokinetics (study of the action of a drug in the body) in these children

NCT ID: NCT00793858 Withdrawn - Allergic Rhinitis Clinical Trials

A Pilot Investigation of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray

Start date: February 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to measure the amount of a nasal steroid spray (ciclesonide) absorbed by the tissue in the nose 2 hours after having this study drug sprayed in the nose

NCT ID: NCT00791973 Completed - Allergic Rhinitis Clinical Trials

Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen

Start date: November 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to help us to a better understanding of how nose and eye symptoms are related in patients with allergies.

NCT ID: NCT00791102 Completed - Allergic Rhinitis Clinical Trials

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

Start date: January 2010
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to see whether ASP-1001 when given as a nasal spray is safe and can reduce the signs and symptoms of allergic rhinitis (hayfever) following nasal challenge with antigen.

NCT ID: NCT00789152 Completed - Allergic Rhinitis Clinical Trials

The Effect of Desloratadine and Levocetirizine on Nasal Obstruction (Study P03609)

Start date: December 1, 2003
Phase: Phase 3
Study type: Interventional

This was a study to measure the ability of desloratadine and levocetirizine to decrease nasal obstruction in subjects who had study-induced allergic rhinitis. Study participants had allergic rhinitis symptoms induced in a Vienna Challenge Chamber and then received desloratadine or levocetirizine for 8 days. After at least a 10 to 35-day washout period (time when no drug is given), subjects received the opposite treatment for 8 days. Subjects had their total nasal symptom measured.on the 8th day of each treatment period.

NCT ID: NCT00787631 Not yet recruiting - Allergic Rhinitis Clinical Trials

Analysis of Immunological Reactions to Foods in Birch Pollen-Allergic Patients

Start date: December 2008
Phase: N/A
Study type: Observational

A high number of birch pollen-allergic individuals develop hypersensitivity reactions to certain foods, e.g. apples. This food allergy is due to immunological cross-reactivity. Birch pollen-related foods contain proteins, e.g. Mal d 1 in apple, that are structurally related with the major birch pollen allergen, Bet v 1. Hence IgE antibodies and T lymphocytes specific for Bet v 1 recognize these food proteins which results in activation of the immune system and, consequently, in clinical symptoms. In the present study the investigators intend to investigate if and how the consumption of birch pollen-related food allergens affects birch pollen allergy. In other words, the investigators are interested to analyse whether Bet v 1-related food allergens activate Bet v 1-specific memory cells and thus, contribute to the maintenance of the pollen allergy outside the pollen season. Data obtained in this study will help to clarify the immunological and clinical role of cross-reactivity between pollen and food allergies and will reveal whether avoidance of such foods should be recommended for the patients. Finally, novel approaches for diagnosis and therapy of pollen-related food allergens can be developed.

NCT ID: NCT00783458 Completed - Allergic Rhinitis Clinical Trials

Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04208)

Start date: December 1, 2004
Phase: Phase 4
Study type: Interventional

This was a one-day single dose trial conducted to compare patient's preference for Nasonex® (mometasone) versus Flonase® nasal spray. Each patient was randomized to take one dose (2 sprays in each nostril) of Nasonex or Flonase. Thirty minutes later, each patient was to take one dose of the opposite medication. Questionnaires were given to each patient after each drug dose to evaluate patient product preference.

NCT ID: NCT00783237 Completed - Allergic Rhinitis Clinical Trials

Onset of Effect of Mometasone Nasal Spray in Induced Allergic Rhinitis (Study P03431)

Start date: December 1, 2003
Phase: Phase 4
Study type: Interventional

This was a single-dose study to determine the time it takes for mometasone furoate nasal spray to go in effect, after a single dose of 2 sprays per nostril. Patients who are eligible were exposed to ragweed pollen for 3 hours on one or two occasions. Patients who experienced adequate symptoms during the pollen exposure phase came back for a Treatment Phase visit. During the Treatment Phase visit, patients were exposed to ragweed pollen for 2 hours and then received either mometasone or placebo nasal spray. Symptom evaluations began on the patients every hour for the next 11 hours.